Skip to main content
ORGO logo

Organogenesis Holdings Inc.

ORGONASDAQHealthcareDrug Manufacturers - Specialty & Generic

$0.94Today:- (-)1Y −74.94%

As of Oct 26, 2026 close

Market cap
$120.36M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.93$7.08
Volume (live)
-
Avg. volume (3M)
765.55K

Organogenesis Holdings (ORGO) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Organogenesis Holdings used $10.31M of cash in operating activities and spent $14.15M on capital expenditures. That left free cash flow of −$24.46M.

Organogenesis Holdings Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Organogenesis Holdings Inc. (ORGO) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income37.030.864.9515.5394.9017.23-40.45-64.83-2.09
Depreciation & Amortization26.9425.3723.4518.0316.688.189.436.985.63
Deferred Income Tax9.50-10.722.011.98-31.980.110.110.190.00
Stock Based Compensation13.3010.589.006.553.861.660.941.080.92
Change in Working Capital-132.38-48.89-18.07-34.08-39.29-27.76-9.67-22.401.51
Change in Accounts Receivable-115.80-31.805.54-8.77-30.23-17.57-4.69-7.11-7.01
Change in Inventory-17.92-6.20-8.18-9.41-9.30-6.70-11.06-5.00-1.49
Change in Accounts Payable-0.53-2.37-0.113.263.85-4.104.70-0.060.00
Change in Other Working Capital15.738.9112.36-7.31-3.600.611.39-10.231.51
Other Operating Activities15.738.9111.0418.8317.806.036.1218.25-0.16
Net Cash from Operating Activities-10.3114.2130.9224.8661.985.47-33.53-60.74-0.59
Investing Activities
Capital Expenditures-14.15-10.03-24.36-33.90-31.22-17.68-6.23-1.86-2.43
Acquisitions0.000.000.000.000.00-5.820.000.00-11.79
Other Investing Activities0.000.000.000.000.000.000.000.00-0.66
Net Cash from Investing Activities-14.15-10.03-24.36-33.90-31.22-23.50-6.23-1.86-14.87
Financing Activities
Debt Repayment-1.17-67.64-4.69-2.81-2.01-15.9137.231.070.10
Common Stock Issued0.160.000.002.072.2064.7350.3492.00-0.43
Common Stock Repurchased0.00-25.48-0.33-0.650.000.00-6.760.000.00
Dividends Paid0.00-1.800.000.000.000.000.000.000.00
Other Financing Activities-16.35-1.18-0.49-0.61-1.22-6.35-2.08-11.4319.19
Net Cash from Financing Activities-17.3627.64-5.51-2.20-1.0442.4778.7381.64-0.33
Summary
Net Change in Cash-41.8231.811.05-11.2429.7224.4438.9719.05-0.91
Cash at Beginning of Period136.15104.34103.29114.5384.8160.3721.412.361.04
Cash at End of Period94.33136.15104.34103.29114.5384.8160.3721.410.13
Free Cash Flow-24.464.186.55-9.0430.76-12.21-39.76-62.60-3.01
Supplemental Disclosures
Interest Paid-4.975.442.655.799.61---
Income Taxes Paid-6.973.051.200.610.06---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Organogenesis Holdings Cash Flow

What is Organogenesis Holdings's free cash flow?

Organogenesis Holdings had negative free cash flow of $24.46M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$10.31M minus $14.15M of capital expenditures.

How much does Organogenesis Holdings spend on capital expenditures?

Organogenesis Holdings spent $14.15M on capital expenditures in fiscal 2025, compared with $10.03M a year earlier.

Does Organogenesis Holdings pay dividends or buy back shares?

Organogenesis Holdings's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition